Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines

British Journal of Cancer

Volumn 92, Issue 4, 2005, Pages 722-728

  Harris, S M ^a   Mistry, P ^a   Freathy, C ^a   Brown, J L ^b   Charlton, P A ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

5 fluorouracil; Colon cancer xenografts; Combination therapy; Irinotecan; XR5944

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; IRINOTECAN; PHENAZINE DERIVATIVE; SULFORHODAMINE B; UNCLASSIFIED DRUG; XR 5944; 7-ETHYL-10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DRUG DERIVATIVE; XR5944;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HCT116; CELL STRAIN HT29; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; COLON TUMOR; DRUG EFFECT; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; FLUOROURACIL; HCT116 CELLS; HT29 CELLS; HUMANS; MICE; MICE, NUDE; PHENAZINES; TRANSPLANTATION, HETEROLOGOUS;

EID: 14944363195     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602403     Document Type: Article

References (28)

1. Allegra CJ, Grem JL (1997) Antimetabolites. In Cancer: Priniciples and Practice of Oncology, DeVita VT, Hellman S, Rosenberg SA (eds) 5th edn, pp 432-452. Philadelphia: Lippincott-Raven
2. Cao S, Durrani FA, Rustum YM (2004) Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumour xenografts. Clin Cancer Res 10: 2561-2569
3. Chou T, Talalay P (1984) Quantitative analysis of dose - effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
4. Cree IA, Di Nicolantonio F, Neale MH, Charlton PA (2001) Ex vivo activity of two novel dual topoisomerase I and II inhibitors XR5944 and XR11576 against solid tumors. Clin Cancer Res 7(Suppl): 3746
5. Cummings J, Boyd G, Ethell BT, Macpherson JS, Burchell B, Smyth JF, Jodrell DI (2002) Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem Pharmacol 63: 607-613
6. Gamage SA, Spicer JA, Finlay GJ, Stewart AJ, Charlton P, Baguley BC, Denny WA (2001) Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. J Med Chem 44: 1407-1415
7. Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P (1997) Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 73: 729-734
8. Guichard S, Hennebelle I, Bugat R, Canal P (1998) Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 55: 667-676
9. Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T, Shimodaira H, Niitani T, Kudo T, Akiyama M, Kimura N, Matsuo M, Mizusawa H, Tanaka N, Koyama H, Namba M, Kanamaru R, Kuroki T (1997) Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinogen 19: 243-253
10. Li LH, Fraser TJ, Olin EJ, Bhuyan BK (1972) Action of camptothecin on mammalian cells in culture. Cancer Res 32: 2643-2650
11. Magrini R, Bhonde MR, Hanski M, Notter M, Scherubl H, Boland CR, Zeitz M, Hanski C (2002) Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 101: 23-31
12. Mans DR, Grivicich I, Peters GJ, Schwartsmann G (1999) Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur J Cancer 35: 1851-1861
13. Mathijssen RHJ, Loos WJ, Verweij J, Sparreboom A (2002) Pharmacology of Topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2: 103-123
14. Okuno S, Harada M, Yano T, Yano S, Kiuchi S, Tsuda N, Sakamura Y, Imai J, Kawaguchi T, Tsujihara K (2000) Complete regression of xenografted human carcinomas by camptothecin analogue - carboxymethyl dextran conjugate (T-0128). Cancer Res 60: 2988-2995
15. Rowinsky EK, Citardi MJ, Noe DA, Donehower RC (1993) Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 119: 727-733
16. Santi DV, McHenry CS, Raines RT, Ivanetich KM (1987) Kinetics and thermodynamics of the interaction of 5-fluoro-2′-deoxyuridylate with thymidylate synthase. Biochemistry 26: 8606-8613
17. Sappal D, Mistry P, Rudolph-Owen LA (2003) MLN944 (XR5944) regulates cell cycle progression by a novel mechanism compared to known topoisomerase inhibitors. AACR 94th Annual Meeting Proceedings Vol. 44, p 546
18. Sappal DS, McClendon AK, Fleming JA, Thoroddsen V, Connolly K, Reimer C, Blackman RK, Bulawa CE, Osheroff N, Charlton P, Rudolph-Owen LA (2004) Biological characterization of MLN944: a potent DNA binding agent. Mol Cancer Ther 3: 47-58
19. Shah MA, Schwartz GK (2001) Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7: 2168-2181
20. Siu WY, Yam CH, Poon RY (1999) G1 versus G2 cell cycle arrest after adriamycin-induced damage in mouse Swiss3T3 cells. FEBS Lett 461: 299-305
21. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112
22. Sobrero AF, Aschele C, Bertino JR (1997) Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol 15(1): 368-381
23. 2 arrest and DNA double strand breaks. Cancer Res 48: 4484-4488
24. Stewart AJ, Mistry P, Dangerfield W, Bootle D, Baker M, Kofler B, Okiji S, Baguley BC, Denny WA, Charlton PA (2001) Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs 12: 359-367
25. Tsao YP, D'Arpa P, Liu LF (1992) The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res 52: 1823-1829
26. Ueno M, Nonaka S, Yamazaki R, Deguchi N, Murai M (2002) SN-38 induces cell cycle arrest and apoptosis in human testicular cancer. Eur Urol 42: 390-397
27. L in addition to BAX and P53 status. Int J Cancer 98: 498-504
28. Voigt W, Matsui S, Yin MB, Burhans WC, Minderman H, Rustum YM (1998) Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis. Anticancer Res 18: 3499-3505